Gilead Sciences portfolio
Operating companyPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 3, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Gilead Sciences reported a $1.6 bn portfolio of 5 positions to the SEC as of the end of Q2 2026. Its largest positions are RCUS, LKFT, ASMB.
Sections with a free account
What it reported after the quarter end (Q2 2026)
The 13F shows the portfolio as of Jun 30, 2026. Since then Gilead Sciences has filed these own trades with the SEC (Form 4, when it owns more than 10% of a company or holds a role in it) and stakes above 5% (13D and 13G). It is not everything it did: only what it must report before the next 13F.
Stake reported in the company · event of Aug 5, 2026 · filed Aug 7, 2026 · filing ↗
What changed this quarter
1 position with a change (1 added to); also, 1 exited through an acquisition or merger. 1 is listed here: those of 0.5 points of the portfolio or more (up to 12).
- Assembly Biosciences+10%more sharesIncreased5.9% → 8.3%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- Arcus BiosciencesRCUS58.8%
- Lakefront BiotherapeuticsLKFT30.3%
- Assembly BiosciencesASMB8.3%
- Kyverna TherapeuticsKYTX2.2%
- Xilio Therapeutics0.4%
Portfolio by sector
- ● Health Care 100%
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Not counted as a concentrated manager: it has fewer than 8 quarters of history; it is an operating company with strategic stakes, not an investment portfolio. Its portfolio is shown all the same, but it is left out of manager counts, the consensus and the ranking. How this is decided
Managers of a similar size
A 13F portfolio value between a third and three times this one, whatever the type of filer. It is not a comparison of what they hold.
- First Light Asset ManagementInvestment firm · $1.6 bn
- Triodos Investment Management BVInvestment firm · $1.6 bn
- MPM BioimpactInvestment firm · $1.6 bn
- Vantage Investment Partners$1.7 bn
- No Street GPInvestment firm · $1.7 bn
- Kopernik Global InvestorsInvestment firm · $1.6 bn